Gene therapy to defeat chronic Hepatitis B
The European Research Council (ERC) just awarded 55 grants to researchers from 17 different countries for their pioneering ideas in science and technology. The name of the program is ERC Proof of Concept: €150,000 dedicated to deepen the practical applicability and industrial value of scientific ideas already established by previous research. Among the winners is Matteo Iannacone, head of the Dynamics of Immune Response Unit at IRCCS Ospedale San Raffaele. Dr. Iannacone already won two other ERC grants.
His project involves the development of a gene therapy approach to reactivate the immune system against chronic HBV infection. It is based on over ten years of research in the field and could be a real turning point in the treatment of one of the most dangerous infectious diseases on a global scale.
A global health priority
There are more than 350 million people in the world with chronic hepatitis B, and about 1 million people die each year from complications caused by the infection, such as cirrhosis of the liver and liver cancer.
"Unlike the acute form of the disease, which usually resolves within a few days, for the chronic form there is no definitive cure today, but only antiviral containment therapies," explains Matteo Iannacone.
Due to the transmission mechanism – through contact with infected blood, from mother to child during childbirth or sexually – and the people unawareness (only about 10% of infected people are aware of their condition), the numbers of patients with chronic hepatitis B are set to increase even further. This is why the World Health Organization has declared HBV a "silent killer" and a global health priority.
San Raffaele's pioneering research on HBV
In patients with the chronic form of infection, the immune system is unable to eradicate the virus, which continues to survive and reproduce within liver cells. However, researchers are still trying to figure out why the immune system fails, in such cases, to eradicate the virus and how to help its job.
The group of Matteo Iannacone – in collaboration with Luca Guidotti, deputy scientific director of San Raffaele, and Renato Ostuni, head of the Genomics of the Innate Immune System Unit of the same institute – has recently revealed the mechanism at the origin of the ineffective immune response against HBV.
In a study published on Nature in 2019, the researchers discovered that in chronic hepatitis B the T lymphocytes are dysfunctional since their activation, which occurs through direct contact with liver cells infected by the virus.
"Thanks to advanced imaging and genomics techniques, we have drawn a detailed portrait of these dysfunctional T lymphocytes, and we have identified specific molecules that can awaken their action against the virus," says Iannacone.
Among these, the most promising is an immune system messenger molecule called interleukin-2 (IL-2). However, an important obstacle to clinical applications of IL-2 has to be taken into account: the molecule can be toxic if administered systemically to the whole body, since it has a powerful inflammatory action.
A gene therapy approach for chronic hepatitis B
To overcome the problem, scientists aim to administer IL-2 in a targeted manner only to the liver tissue through gene therapy, a technique for which San Raffaele is recognized as a global authority, thanks to the pioneering work of the San Raffaele Telethon Institute of Gene Therapy directed by Luigi Naldini.
"By using viral vectors, we can modify liver cells to make them express IL-2 locally and on command," explains Matteo Iannacone. "The ERC funding will allow us to further refine and test the pre-clinical protocol of the therapy. The final goal is the same as WHO's: to reduce new HBV infections by 90% and mortality by 65% by 2030".